MKI67 and breast cancer: In a study of 237 BC patients without adjuvant systemic treatment, Gudlaugsson et al. [16] reported that Ki67 expression measured by DIA, rather than manual counting, provided better reproducibility and prognostic accuracy, thereby supporting the transition to DIA-based methodologies in clinical settings.